X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-01-05 | ZYME | Galbraith Kenneth | Chair, CEO | S - Sale+OE | $10.79 | -23,904 | 23,762 | -50% | -$257,845 | |||||
| DM | 2024-01-05 | ZYME | Astle Christopher | SVP, CFO | S - Sale+OE | $10.79 | -5,994 | 6,503 | -48% | -$64,656 | |||||
| DM | 2024-01-05 | ZYME | Moore Paul Andrew | Chief Scientific Officer | S - Sale+OE | $10.79 | -9,799 | 7,367 | -57% | -$105,699 | |||||
| D | 2023-12-11 | ZYME | Astle Christopher | SVP, CFO | S - Sale+OE | $9.13 | -886 | 1,997 | -31% | -$8,089 | |||||
2023-06-16 | ZYME | Ecor1 Capital, LLC | 10% | P - Purchase | $8.12 | +3,350,000 | 13,437,473 | +33% | +$27,202,000 | ||||||
2023-03-28 | ZYME | Ecor1 Capital, LLC | 10% | P - Purchase | $8.00 | +200,000 | 10,087,473 | +2% | +$1,600,000 | ||||||
| D | 2023-03-10 | ZYME | Klompas Neil A | Pres, COO | S - Sale+OE | $7.83 | -2,977 | 17,732 | -14% | -$23,298 | |||||
| M | 2023-01-19 | ZYME | Ecor1 Capital, LLC | 10% | P - Purchase | $9.70 | +307,500 | 9,887,473 | +3% | +$2,982,733 | |||||
| M | 2023-01-13 | ZYME | Ecor1 Capital, LLC | 10% | P - Purchase | $9.84 | +985,100 | 9,579,973 | +11% | +$9,697,527 | |||||
| M | 2023-01-10 | ZYME | Ecor1 Capital, LLC | 10% | P - Purchase | $7.67 | +1,026,300 | 8,594,873 | +14% | +$7,874,083 | |||||
| AD | 2022-12-12 | ZYME | Astle Christopher | SVP, CFO | S - Sale+OE | $6.01 | -887 | 1,333 | -40% | -$5,331 | |||||
| AD | 2022-11-10 | ZYME | Josephson Neil | Chief Medical Officer | S - Sale+OE | $8.10 | -2,475 | 14,449 | -15% | -$20,045 | |||||
| D | 2022-12-12 | ZYME | Astle Christopher | SVP, CFO | S - Sale+OE | $6.01 | -887 | 1,333 | -40% | -$5,331 | |||||
| D | 2022-11-10 | ZYME | Josephson Neil | Chief Medical Officer | S - Sale+OE | $8.10 | -2,475 | 14,449 | -15% | -$20,045 | |||||
| A | 2022-10-13 | ZYME | Redmile Group, LLC | 10% | P - Purchase | $5.03 | +30,481 | 6,075,918 | +1% | +$153,435 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |